Description
Darapladib (SB-480848), is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor (IC₅₀ of 0.25 nM). It produces sustained inhibition of plasma Lp-PLA2 activity in humans receiving intensive atorvastatin therapy. Lp-PLA2 inhibition with Darapladib also reduces the development of coronary atherosclerotic plaques.
Darapladib (SB-480848), is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor (IC₅₀ of 0.25 nM). It produces sustained inhibition of plasma Lp-PLA2 activity in humans receiving intensive atorvastatin therapy. Lp-PLA2 inhibition with Darapladib also reduces the development of coronary atherosclerotic plaques.
Alternate Name/Synonyms: N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
Appearance: Crystaline solid
Formulation: N/A
CAS Number: 356057-34-6
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₃₆H₃₈F₄N₄O₂S
Molecular Weight: 666.78
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor
MDL Number: N/A
PubChem CID: 9939609
SMILES: CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F
InChi: InChI=1S/C36H38F4N4O2S/c1-3-42(4-2)20-21-43(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-44-32-7-5-6-31(32)34(46)41-35(44)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3
InChi Key: WDPFJWLDPVQCAJ-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |
Related Products
